Skip to main content
SpringerLink
Log in

Oral Signs of Vesiculobullous and Autoimmune Disease

  • Chapter
  • First Online:
Oral Signs of Systemic Disease

  • 1268 Accesses

Abstract

This chapter is focused on the oral manifestations of vesiculobullous and autoimmune diseases. These diseases often share similar oral presentations with subtle differences. Therefore, eliciting a detailed medical history and a thorough oral examination are necessary, while supporting tests including serologies, biopsies, as well as direct and indirect immunofluorescence are often valuable. Examination of cutaneous skin and non-oral mucosa may offer additional diagnostic and prognostic insights. Oral vesiculobullous and autoimmune diseases can lead to debilitating morbidities such as pain and poor oral intake. These diseases may also serve as windows to internal diseases such as infection and malignancy, which necessitates multidisciplinary care.

This chapter describes the epidemiology, etiopathogenesis, clinical manifestations, differential diagnosis, and treatments of oral vesiculobullous and autoimmune diseases, with an emphasis on their oral signs and symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ahmed AR, Graham J, Jordon RE, Provost TT. Pemphigus: current concepts. Ann Intern Med. 1980;92(3):396–405.

    Google Scholar 

  2. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993;11(3):429–52.

    CAS  PubMed  Google Scholar 

  3. Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up. Int Immunopharmacol. 2016;34:25–31.

    CAS  PubMed  Google Scholar 

  4. Sagi L, Sherer Y, Trau H, Shoenfeld Y. Pemphigus and infectious agents. Autoimmun Rev. 2008;8(1):33–5.

    PubMed  Google Scholar 

  5. Krain LS. Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955–1973. Arch Dermatol. 1974;110(6):862–5.

    CAS  PubMed  Google Scholar 

  6. Helander SD, Rogers RS 3rd. The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J Am Acad Dermatol. 1994;30(1):65–75.

    CAS  PubMed  Google Scholar 

  7. Shamim T, Varghese VI, Shameena PM, Sudha S. Pemphigus vulgaris in oral cavity: clinical analysis of 71 cases. Med Oral Patol Oral Cir Bucal. 2008;13(10):E622–6.

    PubMed  Google Scholar 

  8. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–9.

    CAS  PubMed  Google Scholar 

  9. Robinson JC, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris: a review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(4):349–55.

    CAS  PubMed  Google Scholar 

  10. Ding X, Aoki V, Mascaro JM Jr, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol. 1997;109(4):592–6.

    CAS  PubMed  Google Scholar 

  11. Atzmony L, Hodak E, Gdalevich M, Rosenbaum O, Mimouni D. Treatment of pemphigus vulgaris and pemphigus foliaceus: a systematic review and meta-analysis. Am J Clin Dermatol. 2014;15(6):503–15.

    PubMed  Google Scholar 

  12. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001;144(4):775–80.

    CAS  PubMed  Google Scholar 

  13. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol. 1999;140(1):84–9.

    CAS  PubMed  Google Scholar 

  14. Mignogna MD, Lo Muzio L, Galloro G, Satriano RA, Ruocco V, Bucci E. Oral pemphigus: clinical significance of esophageal involvement: report of eight cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(2):179–84.

    CAS  PubMed  Google Scholar 

  15. Dagistan S, Goregen M, Miloglu O, Cakur B. Oral pemphigus vulgaris: a case report with review of the literature. J Oral Sci. 2008;50(3):359–62.

    PubMed  Google Scholar 

  16. Meurer M, Millns JL, Rogers RS 3rd, Jordon RE. Oral pemphigus vulgaris. A report of ten cases. Arch Dermatol. 1977;113(11):1520–4.

    CAS  PubMed  Google Scholar 

  17. Sirois D, Leigh JE, Sollecito TP. Oral pemphigus vulgaris preceding cutaneous lesions: recognition and diagnosis. J Am Dent Assoc. 2000;131(8):1156–60.

    CAS  PubMed  Google Scholar 

  18. Vinay K, Kanwar AJ, Mittal A, Dogra S, Minz RW, Hashimoto T. Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris. JAMA Dermatol. 2015;151(8):878–82.

    PubMed  Google Scholar 

  19. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol. 1996;34(4):645–52.

    CAS  PubMed  Google Scholar 

  20. Rogers RS 3rd, Van Hale HM. Immunopathologic diagnosis of oral mucosal inflammatory diseases. Australas J Dermatol. 1986;27(2):51–7.

    PubMed  Google Scholar 

  21. Harman KE, Albert S, Black MM, British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149(5):926–37.

    CAS  PubMed  Google Scholar 

  22. Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos MI, Mourellou ON, Antoniades DZ. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J Dermatol. 2007;46(4):356–61.

    PubMed  Google Scholar 

  23. Tabrizi MN, Chams-Davatchi C, Esmaeeli N, Noormohammadpoor P, Safar F, Etemadzadeh H, et al. Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2007;21(1):79–84.

    CAS  PubMed  Google Scholar 

  24. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729–35.

    CAS  PubMed  Google Scholar 

  25. Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011;50(8):905–14.

    PubMed  Google Scholar 

  26. Poot AM, Diercks GF, Kramer D, Schepens I, Klunder G, Hashimoto T, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol. 2013;169(5):1016–24.

    CAS  PubMed  Google Scholar 

  27. Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. 2013;54(4):241–50.

    PubMed  Google Scholar 

  28. Poot AM, Siland J, Jonkman MF, Pas HH, Diercks GF. Direct and indirect immunofluorescence staining patterns in the diagnosis of paraneoplastic pemphigus. Br J Dermatol. 2016;174(4):912–5.

    CAS  PubMed  Google Scholar 

  29. Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43(4):619–26.

    CAS  PubMed  Google Scholar 

  30. Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 1995;32(3):441–7.

    CAS  PubMed  Google Scholar 

  31. Murrell DF. Blistering diseases: clinical features, pathogenesis, treatment. New York: Springer; 2015. p. XXI.. 752

    Google Scholar 

  32. Schoen H, Foedinger D, Derfler K, Amann G, Rappersberger K, Stingl G, Volc-Platzer B. Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol. 1998;134(6):706–10.

    CAS  PubMed  Google Scholar 

  33. Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman’s tumor. Dermatology. 1995;190(3):245–50.

    CAS  PubMed  Google Scholar 

  34. Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Bang K, Deleuran M, et al. Alemtuzumab (ALZ) is an effective treatment for both primary and relapsed severe paraneoplastic pemphigus (PNP) associated to B-cell chronic lymphocytic leukemia (CLL). Blood. 2007;110(11):1.

    Google Scholar 

  35. Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol. 1992;128(8):1091–5.

    CAS  PubMed  Google Scholar 

  36. Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol. 1999;40(5 Pt 1):750–4.

    CAS  PubMed  Google Scholar 

  37. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40(6):553–62.

    PubMed  Google Scholar 

  38. Ghigliotti G, Di Zenzo G, Cozzani E, Rongioletti F, De Col E, Pastorino C, et al. Paraneoplastic autoimmune multi-organ syndrome: association with retroperitoneal Kaposi’s sarcoma. Acta Derm Venereol. 2016;96(2):261–2.

    CAS  PubMed  Google Scholar 

  39. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004;9(1):29–33.

    PubMed  Google Scholar 

  40. Kimyai-Asadi A, Jih MH. Paraneoplastic pemphigus. Int J Dermatol. 2001;40(6):367–72.

    CAS  PubMed  Google Scholar 

  41. Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin. 1993;11(3):473–81.

    CAS  PubMed  Google Scholar 

  42. Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol. 2007;34(8):503–11.

    CAS  PubMed  Google Scholar 

  43. Namba C, Tohyama M, Hanakawa Y, Murakami M, Shirakata Y, Matsumoto T, et al. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin. J Dermatol. 2016;43(4):419–22.

    CAS  PubMed  Google Scholar 

  44. Ghandi N, Ghanadan A, Azizian MR, Hejazi P, Aghazadeh N, Tavousi P, et al. Paraneoplastic pemphigus associated with inflammatory myofibroblastic tumour of the mediastinum: a favourable response to treatment and review of the literature. Australas J Dermatol. 2015;56(2):120–3.

    PubMed  Google Scholar 

  45. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol. 1993;129(7):883–6.

    CAS  PubMed  Google Scholar 

  46. Didona D, Paolino G, Richetta A, Cantisani C, Moliterni E, Calvieri S, et al. Paraneoplastic pemphigus: a trait d’union between dermatology and oncology. Adv Mod Oncol Res. 2015;1(2):7.

    Google Scholar 

  47. Descamps V, Belaich S. Paraneoplastic pemphigus. Presse Med. 1999;28(7):363–7.

    CAS  PubMed  Google Scholar 

  48. Martel P, Joly P. Paraneoplastic pemphigus. Ann Dermatol Venereol. 2001;128(11):1256–9.

    CAS  PubMed  Google Scholar 

  49. Preisz K, Karpati S. Paraneoplastic pemphigus. Orv Hetil. 2007;148(21):979–83.

    PubMed  Google Scholar 

  50. Wang R, Li J, Wang M, Hao H, Chen X, Li R, et al. Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis. Br J Dermatol. 2015;172(4):968–75.

    CAS  PubMed  Google Scholar 

  51. Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148(10):1165–72.

    PubMed  Google Scholar 

  52. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66(2):142–4.

    CAS  PubMed  Google Scholar 

  53. Kitagawa C, Nakajima K, Aoyama Y, Fujioka A, Nakajima H, Tarutani M, et al. A typical case of paraneoplastic pemphigus without detection of malignancy: effectiveness of plasma exchange. Acta Derm Venereol. 2014;94(3):359–61.

    PubMed  Google Scholar 

  54. Williams JV, Marks JG Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol. 2000;142(3):506–8.

    CAS  PubMed  Google Scholar 

  55. Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev. 2014;13(4–5):477–81.

    CAS  PubMed  Google Scholar 

  56. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32.

    PubMed  Google Scholar 

  57. Laskaris G, Nicolis G. Immunopathology of oral mucosa in bullous pemphigoid. Oral Surg Oral Med Oral Pathol. 1980;50(4):340–5.

    CAS  PubMed  Google Scholar 

  58. Chuah SY, Tan SH, Chua SH, Tang MB, Lim YL, Neoh CY, et al. A retrospective review of the therapeutic response with remission in patients with newly diagnosed bullous pemphigoid. Australas J Dermatol. 2014;55(2):149–51.

    PubMed  Google Scholar 

  59. Hodge L, Marsden RA, Black MM, Bhogal B, Corbett MF. Bullous pemphigoid: the frequency of mucosal involvement and concurrent malignancy related to indirect immunofluorescence findings. Br J Dermatol. 1981;105(1):65–9.

    CAS  PubMed  Google Scholar 

  60. Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol. 2013;31(4):391–9.

    PubMed  Google Scholar 

  61. Person JR, Rogers RS 3rd. Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations. Mayo Clin Proc. 1977;52(1):54–66.

    CAS  PubMed  Google Scholar 

  62. Shklar G, Meyer I, Zacarian SA. Oral lesions in bullous pemphigoid. Arch Dermatol. 1969;99(6):663–70.

    CAS  PubMed  Google Scholar 

  63. Venning VA, Frith PA, Bron AJ, Millard PR, Wojnarowska F. Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study. Br J Dermatol. 1988;118(1):7–15.

    CAS  PubMed  Google Scholar 

  64. Williams DM. Vesiculo-bullous mucocutaneous disease: benign mucous membrane and bullous pemphigoid. J Oral Pathol Med. 1990;19(1):16–23.

    CAS  PubMed  Google Scholar 

  65. Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL. Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid. J Invest Dermatol. 1996;107(1):136–9.

    CAS  PubMed  Google Scholar 

  66. Carrozzo M, Dametto E, Fasano ME, Broccoletti R, Carbone M, Rendine S, et al. Interleukin-4RA gene polymorphism is associated with oral mucous membrane pemphigoid. Oral Dis. 2014;20(3):275–80.

    CAS  PubMed  Google Scholar 

  67. Oyama N, Setterfield JF, Powell AM, Sakuma-Oyama Y, Albert S, Bhogal BS, et al. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol. 2006;154(1):90–8.

    CAS  PubMed  Google Scholar 

  68. Rabelo DF, Nguyen T, Caufield BA, Ahmed AR. Mucous membrane pemphigoid in two half-sisters. The potential roles of autoantibodies to beta4 integrin subunits and HLA-DQbeta1*0301. J Dermatol Case Rep. 2014;8(1):9–12.

    PubMed  PubMed Central  Google Scholar 

  69. Xu HH, Werth VP, Parisi E, Sollecito TP. Mucous membrane pemphigoid. Dent Clin N Am. 2013;57(4):611–30.

    PubMed  Google Scholar 

  70. Shklar G, McCarthy PL. Oral lesions of mucous membrane pemphigoid. A study of 85 cases. Arch Otolaryngol. 1971;93(4):354–64.

    CAS  PubMed  Google Scholar 

  71. Grattan CE, Small D, Kennedy CT, Scully C. Oral herpes simplex infection in bullous pemphigoid. Oral Surg Oral Med Oral Pathol. 1986;61(1):40–3.

    CAS  PubMed  Google Scholar 

  72. Maley A, Warren M, Haberman I, Swerlick R, Kharod-Dholakia B, Feldman R. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol. 2016;74(5):835–40.

    CAS  PubMed  Google Scholar 

  73. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–9.

    PubMed  Google Scholar 

  74. Setterfield J, Shirlaw PJ, Kerr-Muir M, Neill S, Bhogal BS, Morgan P, et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br J Dermatol. 1998;138(4):602–10.

    CAS  PubMed  Google Scholar 

  75. Ali S, Kelly C, Challacombe SJ, Donaldson AN, Dart JK, Gleeson M, et al. Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid. Br J Dermatol. 2016;174(5):1022–9.

    CAS  PubMed  Google Scholar 

  76. Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol. 2005;6(2):93–103.

    PubMed  Google Scholar 

  77. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol. 2006;142(11):1457–61.

    CAS  PubMed  Google Scholar 

  78. Rogers RS 3rd. Mucous membrane pemphigoid. Dermatology at the millennium. Nashville: Parthenon Publishing; 1999. p. 5.

    Google Scholar 

  79. Hanson RD, Olsen KD, Rogers RS 3rd. Upper aerodigestive tract manifestations of cicatricial pemphigoid. Ann Otol Rhinol Laryngol. 1988;97(5 Pt 1):493–9.

    CAS  PubMed  Google Scholar 

  80. Darling MR, Daley T. Blistering mucocutaneous diseases of the oral mucosa – a review: part 1. Mucous membrane pemphigoid. J Can Dent Assoc. 2005;71(11):851–4.

    PubMed  Google Scholar 

  81. Di Zenzo G, Carrozzo M, Chan LS. Urban legend series: mucous membrane pemphigoid. Oral Dis. 2014;20(1):35–54.

    PubMed  Google Scholar 

  82. Hayakawa T, Furumura M, Fukano H, Li X, Ishii N, Hamada T, et al. Diagnosis of oral mucous membrane pemphigoid by means of combined serologic testing. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(4):483–96.

    PubMed  Google Scholar 

  83. Messmer EM, Hintschich CR, Partscht K, Messer G, Kampik A. Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications. Ophthalmologe. 2000;97(2):113–20.

    CAS  PubMed  Google Scholar 

  84. Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72(1):168–74.

    PubMed  Google Scholar 

  85. Rogers RS 3rd, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol. 1988;7(3):201–5.

    PubMed  Google Scholar 

  86. Rogers RS, Sheridan PJ, Jordon RE. Desquamative gingivitis. Clinical, histopathologic, and immunopathologic investigations. Oral Surg Oral Med Oral Pathol. 1976;42(3):316–27.

    CAS  PubMed  Google Scholar 

  87. Rogers RS 3rd, Sheridan PJ, Nightingale SH. Desquamative gingivitis: clinical, histopathologic, immunopathologic, and therapeutic observations. J Am Acad Dermatol. 1982;7(6):729–35.

    PubMed  Google Scholar 

  88. Scully C, Lo Muzio L. Oral mucosal diseases: mucous membrane pemphigoid. Br J Oral Maxillofac Surg. 2008;46(5):358–66.

    PubMed  Google Scholar 

  89. Serrano TL, et al. Mucous membrane pemphigoid: diagnosis and sequel. Int Arch Otorhinolaryngol. 2014;18(S 01):1.

    Google Scholar 

  90. Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol. 2013;68(3):499–506.

    CAS  PubMed  Google Scholar 

  91. Taylor J, McMillan R, Shephard M, Setterfield J, Ahmed R, Carrozzo M, et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):161–71 e20.

    CAS  PubMed  Google Scholar 

  92. Yeh SW, Usman AQ, Ahmed AR. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol. 2004;112(3):268–72.

    CAS  PubMed  Google Scholar 

  93. Greer RO, McDowell JD, Hoernig G. Oral lichen planus: a premalignant disease? Pro Pathol Case Rev. 1999;4:7.

    Google Scholar 

  94. Nagao T, Ikeda N, Fukano H, Hashimoto S, Shimozato K, Warnakulasuriya S. Incidence rates for oral leukoplakia and lichen planus in a Japanese population. J Oral Pathol Med. 2005;34(9):532–9.

    PubMed  Google Scholar 

  95. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol. 2010;28(1):100–8.

    PubMed  Google Scholar 

  96. Porter SR, Kirby A, Olsen I, Barrett W. Immunologic aspects of dermal and oral lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83(3):358–66.

    CAS  PubMed  Google Scholar 

  97. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(2):164–78.

    PubMed  Google Scholar 

  98. Au J, Patel D, Campbell JH. Oral lichen planus. Oral Maxillofac Surg Clin N Am. 2013;25(1):93–100.. vii

    Google Scholar 

  99. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007;49(2):89–106.

    PubMed  Google Scholar 

  100. Laeijendecker R, Dekker SK, Burger PM, Mulder PG, Van Joost T, Neumann MH. Oral lichen planus and allergy to dental amalgam restorations. Arch Dermatol. 2004;140(12):1434–8.

    PubMed  Google Scholar 

  101. Olson MA, Rogers RS 3rd, Bruce AJ. Oral lichen planus. Clin Dermatol. 2016;34(4):495–504.

    PubMed  Google Scholar 

  102. Parashar P. Oral lichen planus. Otolaryngol Clin N Am. 2011;44(1):89–107.. vi

    Google Scholar 

  103. Pavlovsky L, Israeli M, Sagy E, Berg AL, David M, Shemer A, et al. Lichen planopilaris is associated with HLA DRB1*11 and DQB1*03 alleles. Acta Derm Venereol. 2015;95(2):177–80.

    PubMed  Google Scholar 

  104. Sugerman PB, Savage NW, Zhou X, Walsh LJ, Bigby M. Oral lichen planus. Clin Dermatol. 2000;18(5):533–9.

    CAS  PubMed  Google Scholar 

  105. Wetter DA, Davis MD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol. 2010;62(1):45–53.

    CAS  PubMed  Google Scholar 

  106. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol. 1983;8(6):763–75.

    CAS  PubMed  Google Scholar 

  107. Scully C, Bagan J. Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg. 2008;46(2):90–5.

    PubMed  Google Scholar 

  108. Ayangco L, Rogers RS 3rd. Oral manifestations of erythema multiforme. Dermatol Clin. 2003;21(1):195–205.

    PubMed  Google Scholar 

  109. Lozada-Nur F, Gorsky M, Silverman S Jr. Oral erythema multiforme: clinical observations and treatment of 95 patients. Oral Surg Oral Med Oral Pathol. 1989;67(1):36–40.

    CAS  PubMed  Google Scholar 

  110. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51(8):889–902.

    PubMed  Google Scholar 

  111. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taïeb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child. 2000;83(4):347–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  112. Bakis S, Zagarella S. Intermittent oral cyclosporin for recurrent herpes simplex-associated erythema multiforme. Australas J Dermatol. 2005;46(1):18–20.

    PubMed  Google Scholar 

  113. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539–43.

    CAS  PubMed  Google Scholar 

  114. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.

    CAS  PubMed  Google Scholar 

  115. Brown RS. Oral erythema multiforme: trends and clinical findings of a large retrospective: European case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(6):681.

    PubMed  Google Scholar 

  116. Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72(2):239–45.

    PubMed  Google Scholar 

  117. Celentano A, Tovaru S, Yap T, Adamo D, Aria M, Mignogna MD. Oral erythema multiforme: trends and clinical findings of a large retrospective European case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(6):707–16.

    PubMed  Google Scholar 

  118. Joseph RH, Haddad FA, Matthews AL, Maroufi A, Monroe B, Reynolds M. Erythema multiforme after orf virus infection: a report of two cases and literature review. Epidemiol Infect. 2015;143(2):385–90.

    CAS  PubMed  Google Scholar 

  119. Joseph TI, Vargheese G, George D, Sathyan P. Drug induced oral erythema multiforme: a rare and less recognized variant of erythema multiforme. J Oral Maxillofac Pathol. 2012;16(1):145–8.

    PubMed  PubMed Central  Google Scholar 

  120. Kishore BN, Ankadavar NS, Kamath GH, Martis J. Varicella zoster with erythema multiforme in a young girl: a rare association. Indian J Dermatol. 2014;59(3):299–301.

    PubMed  PubMed Central  Google Scholar 

  121. Patil B, Hegde S, Naik S, Sharma R. Oral blistering – report of two cases of erythema multiforme & literature review. J Clin Diagn Res. 2013;7(9):2080–3.

    PubMed  PubMed Central  Google Scholar 

  122. Rogers RS 3rd. Pseudo-Behcet’s disease. Dermatol Clin. 2003;21(1):49–61.

    PubMed  Google Scholar 

  123. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin N Am. 2013;57(4):583–96.

    PubMed  Google Scholar 

  124. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173 e1–13.. quiz 185–6

    Google Scholar 

  125. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13(1):49–54.

    PubMed  Google Scholar 

  126. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.

    CAS  PubMed  Google Scholar 

  127. Lu N, Rai SK, Terkeltaub R, Kim SC, Menendez ME, Choi HK. Racial disparities in the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Semin Arthritis Rheum. 2016;46(2):253–8.

    PubMed  PubMed Central  Google Scholar 

  128. Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129(11):1221–5.

    PubMed  Google Scholar 

  129. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187 e1–16.. quiz 203–4

    Google Scholar 

  130. Stern RS. Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis. JAMA. 2014;312(15):1590–1.

    PubMed  Google Scholar 

  131. Salmi TT, Hervonen K, Kautiainen H, Collin P, Reunala T. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol. 2011;165(2):354–9.

    CAS  PubMed  Google Scholar 

  132. Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol. 2011;64(6):1017–24; quiz 1025–6

    PubMed  Google Scholar 

  133. Smith JB, Tulloch JE, Meyer LJ, Zone JJ. The incidence and prevalence of dermatitis herpetiformis in Utah. Arch Dermatol. 1992;128(12):1608–10.

    CAS  PubMed  Google Scholar 

  134. Karpati S. Dermatitis herpetiformis: close to unravelling a disease. J Dermatol Sci. 2004;34(2):83–90.

    CAS  PubMed  Google Scholar 

  135. Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol. 2011;64(6):1027–33; quiz 1033–4

    PubMed  Google Scholar 

  136. Peters MS, McEvoy MT. IgA antiendomysial antibodies in dermatitis herpetiformis. J Am Acad Dermatol. 1989;21(6):1225–31.

    CAS  PubMed  Google Scholar 

  137. Dieterich W, Laag E, Bruckner-Tuderman L, Reunala T, Kárpáti S, Zágoni T, et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol. 1999;113(1):133–6.

    CAS  PubMed  Google Scholar 

  138. Griffiths CE, Leonard JN, Fry L. Dermatitis herpetiformis exacerbated by indomethacin. Br J Dermatol. 1985;112(4):443–5.

    CAS  PubMed  Google Scholar 

  139. Bardella MT, Fredella C, Saladino V, Trovato C, Cesana BM, Quatrini M, et al. Gluten intolerance: gender- and age-related differences in symptoms. Scand J Gastroenterol. 2005;40(1):15–9.

    PubMed  Google Scholar 

  140. Economopoulou P, Laskaris G. Dermatitis herpetiformis: oral lesions as an early manifestation. Oral Surg Oral Med Oral Pathol. 1986;62(1):77–80.

    CAS  PubMed  Google Scholar 

  141. Fraser NG, Kerr NW, Donald D. Oral lesions in dermatitis herpetiformis. Br J Dermatol. 1973;89(5):439–50.

    CAS  PubMed  Google Scholar 

  142. Sansaricqa FC, Petronic-Rosic V. Dermatitis herpetiformis: what practitioners need to know. Pract Gastr. 2012;111:39–44.

    Google Scholar 

  143. Hietanen J, Reunala T. IgA deposits in the oral mucosa of patients with dermatitis herpetiformis and linear IgA disease. Scand J Dent Res. 1984;92(3):230–4.

    CAS  PubMed  Google Scholar 

  144. Katz SI. Dermatitis herpetiformis. Clinical, histologic, therapeutic and laboratory clues. Int J Dermatol. 1978;17(7):529–35.

    CAS  PubMed  Google Scholar 

  145. Nicolas ME, Krause PK, Gibson LE, Murray JA. Dermatitis herpetiformis. Int J Dermatol. 2003;42(8):588–600.

    PubMed  Google Scholar 

  146. Nisengard RJ, Chorzelski T, Maciejowska E, Kryst L. Dermatitis herpetiformis: IgA deposits in gingiva, buccal mucosa, and skin. Oral Surg Oral Med Oral Pathol. 1982;54(1):22–5.

    CAS  PubMed  Google Scholar 

  147. Sawant P, Kshar A, Byakodi R, Paranjpe A. Immunofluorescence in oral mucosal diseases –a review. Oral Surg Oral Med Oral Radiol. 2014;2(1):5.

    Google Scholar 

  148. Chan LS, Regezi JA, Cooper KD. Oral manifestations of linear IgA disease. J Am Acad Dermatol. 1990;22(2 Pt 2):362–5.

    CAS  PubMed  Google Scholar 

  149. Kelly SE, Frith PA, Millard PR, Wojnarowska F, Black MM. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol. 1988;119(2):161–70.

    CAS  PubMed  Google Scholar 

  150. Leonard JN, Wright P, Williams DM, Gilkes JJ, Haffenden GP, McMinn RM, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol. 1984;110(3):307–14.

    CAS  PubMed  Google Scholar 

  151. Porter SR, Bain SE, Scully CM. Linear IgA disease manifesting as recalcitrant desquamative gingivitis. Oral Surg Oral Med Oral Pathol. 1992;74(2):179–82.

    CAS  PubMed  Google Scholar 

  152. O’Regan E, Bane A, Flint S, Timon C, Toner M. Linear IgA disease presenting as desquamative gingivitis: a pattern poorly recognized in medicine. Arch Otolaryngol Head Neck Surg. 2004;130(4):469–72.

    PubMed  Google Scholar 

  153. Fine JD, Neises GR, Katz SI. Immunofluorescence and immunoelectron microscopic studies in cicatricial pemphigoid. J Invest Dermatol. 1984;82(1):39–43.

    CAS  PubMed  Google Scholar 

  154. Coelho S, Tellechea O, Reis JP, Mariano A, Figueiredo A. Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Int J Dermatol. 2006;45(8):995–6.

    PubMed  Google Scholar 

  155. Cohen DM, Bhattacharyya I, Zunt SL, Tomich CE. Linear IgA disease histopathologically and clinically masquerading as lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(2):196–201.

    CAS  PubMed  Google Scholar 

  156. Green ST, Natarajan S. Linear IgA disease and oesophageal carcinoma. J R Soc Med. 1987;80(1):48–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  157. Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol. 1996;106(4):734–8.

    CAS  PubMed  Google Scholar 

  158. McEvoy MT, Connolly SM. Linear IgA dermatosis: association with malignancy. J Am Acad Dermatol. 1990;22(1):59–63.

    CAS  PubMed  Google Scholar 

  159. Ongole R, Praveen BN, editors. Textbook of oral medicine, oral diagnosis and oral radiology. 2nd ed. New Delhi: Elsevier India; 2014. p. 924.

    Google Scholar 

  160. Sago J, Hall RP. Dapsone. Dermatol Ther. 2002;15:11.

    Google Scholar 

  161. Yomada M, Komai A, Hashimato T. Sublamina densa-type linear IgA bullous dermatosis successfully treated with oral tetracycline and niacinamide. Br J Dermatol. 1999;141(3):608–9.

    CAS  PubMed  Google Scholar 

  162. Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931–50.

    PubMed  Google Scholar 

  163. Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol. 2012;30(1):70–7.

    PubMed  Google Scholar 

  164. Youssefian L, Vahidnezhad H, Uitto J. Kindler syndrome. In: Pagon RA, et al., editors. GeneReviews (R). Seattle: University of Washington; 1993.

    Google Scholar 

  165. Murauer EM, Koller U, Pellegrini G, De Luca M, Bauer JW. Advances in gene/cell therapy in epidermolysis bullosa. Keio J Med. 2015;64(2):21–5.

    CAS  PubMed  Google Scholar 

  166. Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, et al. TALEN-based gene correction for epidermolysis bullosa. Mol Ther. 2013;21(6):1151–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  167. Tolar J, McGrath JA, Xia L, Riddle MJ, Lees CJ, Eide C, et al. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2014;134(5):1246–54.

    CAS  PubMed  Google Scholar 

  168. Aberdam D, Aguzzi A, Baudoin C, Galliano MF, Ortonne JP, Meneguzzi G. Developmental expression of nicein adhesion protein (laminin-5) subunits suggests multiple morphogenic roles. Cell Adhes Commun. 1994;2(2):115–29.

    CAS  PubMed  Google Scholar 

  169. Asaka T, Akiyama M, Domon T, Nishie W, Natsuga K, Fujita Y, et al. Type XVII collagen is a key player in tooth enamel formation. Am J Pathol. 2009;174(1):91–100.

    CAS  PubMed  PubMed Central  Google Scholar 

  170. Kudva P, Jain R. Periodontal manifestation of epidermolysis bullosa: looking through the lens. J Indian Soc Periodontol. 2016;20(1):72–4.

    PubMed  PubMed Central  Google Scholar 

  171. Siegel DH, Ashton GH, Penagos HG, Lee JV, Feiler HS, Wilhelmsen KC, et al. Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet. 2003;73(1):174–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  172. Wright JT. Oral manifestations in the epidermolysis bullosa spectrum. Dermatol Clin. 2010;28(1):159–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  173. Wright JT, Fine JD, Johnson LB. Oral soft tissues in hereditary epidermolysis bullosa. Oral Surg Oral Med Oral Pathol. 1991;71(4):440–6.

    CAS  PubMed  Google Scholar 

  174. Stephenson P, Lamey PJ, Scully C, Prime SS. Angina bullosa haemorrhagica: clinical and laboratory features in 30 patients. Oral Surg Oral Med Oral Pathol. 1987;63(5):560–5.

    CAS  PubMed  Google Scholar 

  175. High AS, Main DM. Angina bullosa haemorrhagica: a complication of long-term steroid inhaler use. Br Dent J. 1988;165(5):176–9.

    CAS  PubMed  Google Scholar 

  176. Kurban M, Kibbi AG, Ghosn S. Expanding the histologic spectrum of angina bullosa hemorrhagica: report of one case. Am J Dermatopathol. 2007;29(5):477–9.

    PubMed  Google Scholar 

  177. Shashikumar B, Reddy RR, Harish M. Oral hemorrhagic blister: an enigma. Indian J Dermatol. 2013;58(5):407.

    PubMed  PubMed Central  Google Scholar 

  178. Shoor H, Mutalik S, Pai KM. Angina bullosa haemorrhagica. BMJ Case Rep. 2013;2013:bcr2013200352.

    PubMed  PubMed Central  Google Scholar 

  179. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.

    PubMed  Google Scholar 

  180. Nagarajan A, Masthan MK, Sankar LS, Narayanasamy AB, Elumalai R. Oral manifestations of vitiligo. Indian J Dermatol. 2015;60(1):103.

    PubMed  PubMed Central  Google Scholar 

  181. Lawoyin D, Brown R, Reid E, Sam F, Obayomi T. Concurrent presentation of cutaneous and oral soft tissue vitiligo: a case report and literature review. Int J Dent Sci. 2007;5:5.

    Google Scholar 

  182. Dawber RP. Clinical associations of vitiligo. Postgrad Med J. 1970;46(535):276–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  183. Bordere AC, Lambert J, van Geel N. Current and emerging therapy for the management of vitiligo. Clin Cosmet Investig Dermatol. 2009;2:15–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  184. Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment. J Am Acad Dermatol. 2011;65(3):493–514.

    PubMed  Google Scholar 

  185. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159(5):1051–76.

    CAS  PubMed  Google Scholar 

  186. Whitton ME, Ashcroft DM, Gonzalez U. Therapeutic interventions for vitiligo. J Am Acad Dermatol. 2008;59(4):713–7.

    PubMed  Google Scholar 

  187. Al-Otaibi SR, Zadeh VB, Al-Abdulrazzaq AH, Tarrab SM, Al-Owaidi HA, Mahrous R, et al. Using a 308-nm excimer laser to treat vitiligo in Asians. Acta Dermatovenerol Alp Pannonica Adriat. 2009;18(1):13–9.

    PubMed  Google Scholar 

  188. Ashok N, Karunakaran A, Singh P, Rodrigues J, Ashok N, Tarakji B, et al. Gingival vitiligo: report of a case and review of the literature. Case Rep Dent. 2014;2014:874025.

    PubMed  PubMed Central  Google Scholar 

  189. Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol. 1997;77(6):460–2.

    CAS  PubMed  Google Scholar 

  190. Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2003;28(3):285–7.

    CAS  PubMed  Google Scholar 

  191. Parsad D, Kanwar A. Oral minocycline in the treatment of vitiligo – a preliminary study. Dermatol Ther. 2010;23(3):305–7.

    PubMed  Google Scholar 

  192. Dave S, Thappa DM, Dsouza M. Clinical predictors of outcome in vitiligo. Indian J Dermatol Venereol Leprol. 2002;68(6):323–5.

    PubMed  Google Scholar 

  193. McHepange UO, Gao XH, Liu YY, Liu YB, Ma L, Zhang L, Chen HD. Vitiligo in North-Eastern China: an association between mucosal and acrofacial lesions. Acta Derm Venereol. 2010;90(2):136–40.

    PubMed  Google Scholar 

  194. Powell FC, Dicken CH. Psoriasis and vitiligo. Acta Derm Venereol. 1983;63(3):246–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Mayo Clinic, Rochester, MN, USA

    Michael Z. Wang

  2. Departments of Dermatology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Julia S. Lehman

  3. Department of Dermatology, Mayo Clinic Arizona, Scottsdale, AZ, USA

    Roy Steele Rogers III

Authors
  1. Michael Z. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia S. Lehman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roy Steele Rogers III
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia S. Lehman .

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of California, Davis, Sacramento, CA, USA

    Nasim Fazel

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wang, M.Z., Lehman, J.S., Rogers, R.S. (2019). Oral Signs of Vesiculobullous and Autoimmune Disease. In: Fazel, N. (eds) Oral Signs of Systemic Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-10863-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-10863-2_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-10861-8

  • Online ISBN: 978-3-030-10863-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation